Eternal Search · Ratings · Project Ratings
Brain & Cognitive Longevity
Neurodegeneration, cognitive resilience, and brain aging.
#OverallProjectSci / Brk / Inv
156.9Axxium Life
Axxium Life presents itself as a developer of AI-powered active immunotherapy biologics aimed first at Alzheimer’s prevention and other chronic diseases, using peptide-based vaccines intended to induce patients’ own antibodies against targets such as amyloid-beta and alpha-synuclein. The strongest external support in the provided evidence is not for Axxium’s current flagship claim directly, but for related Vaxxinity/United Biomedical-linked programs: a phase 2a Alzheimer’s study, first-in-human and phase 1 alpha-synuclein studies, mouse synuclein data, and a monkey PCSK9 vaccine study. The main caution is that the most ambitious claims, including a privately controlled Phase 3 Alzheimer’s-prevention position and AI platform performance, are self-reported on company pages and not independently validated in the excerpt.Sci 65.0Brk 60.5Inv 47.6
57%
→
245.1VITA (Hospital del Mar Research
VITA is a Barcelona-based, XPRIZE Healthspan semifinalist project from Hospital del Mar Research Institute, CRG, and IrsiCaixa that proposes a multimodal healthy-aging intervention centered on lamivudine, EGCG, and lifestyle change for older adults at risk of cognitive decline. The strongest public evidence is institutional: funding/selection announcements in May 2025, follow-on reporting tied to prior PENSA work, and a Jan-Jun 2026 recruitment page for a lifestyle-plus-EGCG study in adults aged 60-80 with subjective cognitive concerns. That supports real institutional activity and clinical intent, but not efficacy; public evidence still looks early, non-peer-reviewed, and partly inconsistent about whether lamivudine is already in the human study arm.Sci 46.0Brk 40.2Inv 47.4
45%
→
340.6Mitochondrial Bioenergetics and Ketone
Mitargos appears to be a US startup commercializing an R-1,3-butanediol ketone drink, MiDR1V3, and linking it to a UC San Diego-led XPRIZE Healthspan semifinalist project that plans to test whether ketone-based interventions can improve mitochondrial function and physical, cognitive, and immune outcomes in older adults; however, the supplied evidence is mostly patent/IP and review literature plus a company-linked press release, so project-specific efficacy remains unproven.Sci 43.8Brk 34.9Inv 41.5
41%
→
434.7LiGHT Team (Lithium as a
LiGHT Team appears to center on low- or trace-dose lithium as a neuroprotective strategy for dementia, Parkinson’s disease, and related brain-aging conditions. The provided record supports substantial idea generation and patent activity, plus limited preclinical signal, but not convincing human efficacy. The main attraction is that lithium is biologically active, cheap, and already medically familiar; the main problem is that standard lithium has a narrow therapeutic window and meaningful renal, thyroid, and neurological toxicity, so the project only matters if much lower exposures still produce real CNS benefit.Sci 34.4Brk 34.8Inv 34.9
35%
→